본문 바로가기 주메뉴 바로가기
국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

목차보기

목차 1

주요국 디지털 치료기기의 보건의료기술평가 현황과 시사점 : 독일, 영국, 미국 발전과정을 중심으로 = Health technology assessment of digital therapeutics : developments in Germany, the United Kingdom, and the United States, and implications for Korea / 송인명 ; 김동숙 1

[요약] 1

서론 1

연구방법 2

연구결과 2

고찰 및 시사점 6

결론 7

REFERENCES 7

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
대상포진 백신의 유효성에 대한 신속 체계적 문헌고찰 = A rapid systematic review of effectiveness of herpes zoster vaccine 정채림, 최원석, 윤영경, 성연희, 조자현, 유수연 p. 1-8

보기
주요국 디지털 치료기기의 보건의료기술평가 현황과 시사점 = Health technology assessment of digital therapeutics : developments in Germany, the United Kingdom, and the United States, and implications for Korea : 독일, 영국, 미국 발전과정을 중심으로 송인명, 김동숙 p. 9-16

보기
알츠하이머병 환자의 건강관련 삶의 질 = Health-related quality of life in patients with Alzheimer's disease : a systematic review : 체계적 문헌고찰 정은아, 김미령, 서혜선 p. 17-24

보기
전문가 의견 기반 의약품 광고 가이드라인 및 심의 규정 개선방안 = Improvement of the drug advertisement guideline and review regulation based on expert opinions 전하림, 정재훈 p. 25-30

보기
건강보험심사평가원 소아청소년 환자표본자료를 활용한 폐렴구균 감염 관련 질환의 추세 분석 = Trend analysis of pneumococcal infection-related disease using hira-pediatric patient sample data : focus on the prevalence, direct medical cost, and antibiotic prescriptions : 유병률, 직접의료비용, 항생제 처방을 중심으로 변보경, 박선경 p. 31-37, [1-3]

보기
혈소판 약물 반응검사를 토대로 한 항혈소판제 치료방침의 효과성 평가 = Effectiveness of platelet drug response assay for P2Y12 inhibitor : a systematic review of randomised controlled trials : 체계적 문헌고찰 서재경, 이현아 p. 38-49

보기

참고문헌 (32건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Pear Therapeutics. Pear Therapeutics obtains FDA clearance of the first prescription digital therapeutic to treat disease [Internet]. Boston:Pear Therapeutics [cited 2024 Feb 23]. Available from: https://www.prnewswire.com/news-releases/pear-therapeutics-obtains-fdaclearance-of-the-first-prescription-digital-therapeutic-to-treat-disease-300520068.html. 미소장
2 Federal Institute for Drugs and Medical Devices. The fast-track process for digital health applications (DiGA) according to section 139e SGB V. A guide for manufacturers, service providers and users [Internet]. Bonn: Federal Institute for Drugs and Medical Devices [cited 2024 Feb 23]. Available from: https://www.bfarm.de/SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.html. 미소장
3 Digital Health Global. Digital Health Global Market report 2023:ease of access, shorter development timelines and decreased cost of treatment bolster demand - ResearchAndMarkets.com [Internet]. EVERSANA [cited 2024 Feb 23]. Available from: https://www.digitalhealthglobal. com/digital-health-global-market-report-2023-easeof-access-shorter-development-timelines-and-decreased-cost-oftreatment-bolster-demand-researchandmarkets-com. 미소장
4 Korea Health Industry Development Institute. [Regulatory cases and issues responding to technological innovation Ⅱ: reimbursement for newly emerging medical technologies in digital health]. Cheongju:Korea Health Industry Development Institute;2023. Korean 미소장
5 European Data Protection Supervisor. Digital therapeutics (DTx)[Internet]. Brussels: European Data Protection Supervisor [cited 2024 Jan 9]. Available from: https://edps.europa.eu/press-publications/publications/techsonar/digital-therapeutics-dtx. 미소장
6 Digital Therapeutics Alliance. Understanding DTx [Internet]. Washington, DC: Digital Therapeutics Alliance [cited 2024 Jan 9]. Available from: https://dtxalliance.org/understanding-dtx. 미소장
7 Phan P, Mitragotri S, Zhao Z. Digital therapeutics in the clinic. Bioeng Transl Med 2023;8:e10536. 미소장
8 Wang W, Gellings Lowe N, Jalali A, Murphy SM. Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. J Med Econ 2021;24:61-68. 미소장
9 Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K. Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoecon Outcomes Res 2021;21:69-76. 미소장
10 Sapanel Y, Tadeo X, Brenna CTA, Remus A, Koerber F, Cloutier LM, et al. Economic evaluation associated with clinical-grade mobile app-based digital therapeutic interventions: systematic review. J Med Internet Res 2023;25:e47094. 미소장
11 van Kessel R, Roman-Urrestarazu A, Anderson M, Kyriopoulos I, Field S, Monti G, et al. Mapping factors that affect the uptake of digital therapeutics within health systems: scoping review. J Med Internet Res 2023;25:e48000. 미소장
12 Prodan A, Deimel L, Ahlqvist J, Birov S, Thiel R, Toivanen M, et al. Success factors for scaling up the adoption of digital therapeutics towards the realization of P5 medicine. Front Med (Lausanne) 2022;9:854665. 미소장
13 Federal Ministry of Health. Driving the digital transformation of Germany’s healthcare system for the good of patients [Internet]. Berlin:Federal Ministry of Health [cited 2024 Jan 10]. Available from:https://www.bundesgesundheitsministerium.de/en/digital-healthcareact. 미소장
14 Fürstenau D, Gersch M, Schreiter S. Digital therapeutics (DTx). Bus Inf Syst Eng 2023;65:349-360. 미소장
15 Brönneke JB, Herr A, Reif S, Stern AD. Dynamic HTA for digital health solutions: opportunities and challenges for patient-centered evaluation. Int J Technol Assess Health Care 2023;39:e72. 미소장
16 Lauer W, Löbker W, Höfgen B. [Digital health applications (DiGA):assessment of reimbursability by means of the “DiGA Fast Track”procedure at the Federal Institute for Drugs and Medical Devices (BfArM)]. Bundesgesundheitsbl 2021;64:1232-1240. German 미소장
17 Gerke S, Stern AD, Minssen T. Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries. NPJ Digit Med 2020;3:94. 미소장
18 Dittrich F, Mielitz A, Pustozerov E, Lawin D, von Jan U, Albrecht UV. Digital health applications from a government-regulated directory of reimbursable health apps in Germany-a systematic review for evidence and bias. Mhealth 2023;9:35. 미소장
19 Digital Therapeutics Alliance. Digital therapeutics in the United Kingdom [Internet]. Washington, DC: Digital Therapeutics Alliance [cited 2024 Feb 10]. Available from: https://dtxalliance.org/wp-content/uploads/2021/06/DTA_DTx-Overview_UK.pdf. 미소장
20 Unsworth H, Dillon B, Collinson L, Powell H, Salmon M, Oladapo T, et al. The NICE evidence standards framework for digital health and care technologies – Developing and maintaining an innovative evidence framework with global impact. Digit Health 2021;7:20552076211018617. 미소장
21 Yan K, Balijepalli C, Druyts E. The impact of digital therapeutics on current health technology assessment frameworks. Front Digit Health 2021;3:667016. 미소장
22 National Institute for Health and Care Excellence. Evidence standards framework for digital health technologies [Internet]. London:National Institute for Health and Care Excellence [cited 2024 Jan 9]. Available from: https://www.nice.org.uk/corporate/ecd7. 미소장
23 National Institute for Health and Care Excellence. Evidence standards framework for digital health technologies. Section C: evidence standards tables [Internet]. London: National Institute for Health and Care Excellence [cited 2024 Jan 11]. Available from: https://www.nice. org.uk/corporate/ecd7/chapter/section-c-evidence-standards-tables. 미소장
24 NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills | News | News. NICE. NICE, 2022[cited 2024 Feb 26]. Available from: https://www.neuroscience. ox.ac.uk/news/nice-recommends-offering-app-based-treatment-forpeople-with-insomnia-instead-of-sleeping-pills. 미소장
25 Thompson M. 117th Congress (2021-2022): H.R.7051 - access to prescription digital therapeutics act of 2022 [Internet]. Washington, DC: United States Congress [cited 2024 Jan 10]. Available from:https://www.congress.gov/bill/117th-congress/house-bill/7051/related-bills. 미소장
26 Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med 2020;3:159. 미소장
27 보건복지부, 식품의약품안전처. [의료기기산업 육성 및 혁신의료기기 지원법(시행 2020. 5. 1.) (법률 제16405호, 2019. 4. 30., 제정)]. Korean 미소장
28 식품의약품안전처. [디지털치료기기 허가·심사 가이드라인]. 청주: 식품의약품안전처;2020. Korean 미소장
29 식품의약품안전처. [디지털의료제품법(시행 2025. 1. 24.) (법률 제20139호, 2024. 1. 23., 제정)]. Korean 미소장
30 보건복지부, 건강보험심사평가원. [디지털치료기기 건강보험 등재가이드라인]. 세종, 원주: 보건복지부, 건강보험심사평가원;2023. Korean 미소장
31 보건복지부. [2023년 제13차 건강보험정책심의위원회: 디지털치료기기·인공지능 임시등재 방안]. 세종: 보건복지부;2023. Korean 미소장
32 Huh KY, Oh J, Lee S, Yu KS. Clinical evaluation of digital therapeutics:present and future. Healthc Inform Res 2022;28:188-197. 미소장